Atrion (NASDAQ:ATRI) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Atrion (NASDAQ:ATRI) in a research report released on Thursday. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Price Performance

NASDAQ:ATRI opened at $457.65 on Thursday. The business’s 50-day moving average is $456.19 and its two-hundred day moving average is $414.57. Atrion has a 12 month low of $274.98 and a 12 month high of $575.88. The firm has a market capitalization of $805.46 million, a PE ratio of 43.01 and a beta of 0.68.

Atrion (NASDAQ:ATRI) last announced its earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. Atrion had a return on equity of 7.75% and a net margin of 10.60%. The business had revenue of $47.33 million for the quarter.

Atrion Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were given a dividend of $2.20 per share. The ex-dividend date of this dividend was Friday, June 14th. This represents a $8.80 annualized dividend and a dividend yield of 1.92%. Atrion’s dividend payout ratio is presently 82.71%.

Hedge Funds Weigh In On Atrion

Hedge funds and other institutional investors have recently made changes to their positions in the business. Citizens Financial Group Inc. RI bought a new stake in Atrion during the fourth quarter worth approximately $1,114,000. Penn Mutual Asset Management LLC bought a new stake in Atrion during the fourth quarter worth approximately $1,949,000. Jump Financial LLC bought a new stake in Atrion during the fourth quarter worth approximately $234,000. Tower Research Capital LLC TRC increased its holdings in shares of Atrion by 592.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock valued at $102,000 after buying an additional 231 shares in the last quarter. Finally, Quadrant Capital Group LLC bought a new position in shares of Atrion in the fourth quarter valued at $36,000. 66.19% of the stock is currently owned by institutional investors and hedge funds.

Atrion Company Profile

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.